SLS
Sellas Life Sciences Group Inc
12.00$
+4.0%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | 100.0% | 100.0% | 100.0% | – | – | – | – | – | 100.0% | 100.0% | 100.0% | – | – | – | |
| – | – | – | – | – | – | 2.4% | 20.9% | 15.1% | – | – | – | – | – | 19,842.1% | 2.6% | 10.0% | – | – | – | |
| – | – | – | – | – | – | 100.0% | 79.1% | 84.9% | – | – | – | – | – | 100.0% | 97.4% | 90.0% | – | – | – | |
| – | – | – | – | – | – | 717.1% | 847.4% | 304.3% | – | – | – | – | – | 488,526.3% | 281.2% | 3,026.8% | – | – | – | |
| – | – | – | – | – | – | 323.1% | 587.1% | 336.3% | – | – | – | – | – | 505,263.2% | 148.9% | 1,258.2% | – | – | – | |
| – | – | – | – | – | – | 1,040.2% | 1,439.8% | 645.3% | – | – | – | – | – | -993,789.5% | 430.2% | 4,285.0% | – | – | – | |
| – | – | – | – | – | – | -1,040.2% | -1,360.7% | -392.8% | – | – | – | – | – | -893,789.5% | -332.8% | -4,195.0% | – | – | – | |
| – | – | – | – | – | – | 1.6% | 32.4% | 11.9% | – | – | – | – | – | 20,526.3% | 57.3% | 64.9% | – | – | – | |
| – | – | – | – | – | – | -1,686.8% | -3,040.9% | -392.8% | – | – | – | – | – | -882,842.1% | -275.5% | -4,130.1% | – | – | – | |
| – | – | – | – | – | – | -51.6% | 42.3% | -165.7% | – | – | – | – | – | -894.7% | -3.1% | -64.9% | – | – | – | |
| – | – | – | – | – | – | -1,715.8% | -3,083.2% | -392.8% | – | – | – | – | – | -881,947.4% | -272.4% | -4,130.1% | – | – | – | |
| – | – | – | – | – | – | -1,037.8% | 306.7% | -392.8% | – | – | – | – | – | 1,396,015.8% | -241.1% | -3,149.3% | – | – | – |
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.